NCT00141167 is a Phase 3 clinical trial of varenicline in Smoking Cessation, sponsored by Pfizer.

Who is sponsoring NCT00141167?

NCT00141167 is sponsored by Pfizer.

What drugs are being tested in NCT00141167?

Interventions in NCT00141167: varenicline.

What condition does NCT00141167 study?

NCT00141167 studies Smoking Cessation.

Is NCT00141167 still recruiting?

NCT00141167 is currently completed. Last updated 3 September 2010.

Last reviewed 2010-09-03 · How we verify

NCT00141167

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Twelve-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation

Completed Phase 3 Last updated 3 September 2010

What this trial tests

Phase 3 trial testing varenicline in Smoking Cessation in 250 participants. Completed in 1 January 2006.

Timeline

1 February 2005

1 January 2006

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	250
Start date	1 February 2005
Estimated completion	1 January 2006
Sites	10 locations across South Korea, Taiwan

Drugs / interventions tested

varenicline (varenicline) — full drug profile →

Conditions studied

Smoking Cessation — all drugs for Smoking Cessation →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 75, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

4 week continuous quit rate ( 4 week CQR ) for weeks 9 -12

Sponsor's own description

The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interventions for preventing weight gain after smoking cessation.
Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, et al · · 2021 · cited 40× · PMID 34611902 · DOI 10.1002/14651858.cd006219.pub4
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo-controlled studies of varenicline.
Tonstad S, Lawrence D. · · 2017 · cited 27× · PMID 27223809 · DOI 10.1111/jdi.12543

Verify or expand the search:

Other trials of varenicline

Trials testing the same drug.

NCT07145866 — Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) · Phase 4 · not yet recruiting
NCT02854800 — Smoking Cessation & Opioid Dependence Treatment Integration · Phase 2, PHASE3 · completed
NCT01771627 — Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers · NA · completed
NCT01290445 — Varenicline Pregnancy Cohort Study · completed
NCT00781755 — Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal · Phase 4 · withdrawn

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00141167 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 3 September 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00141167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing